Switch theme
Sign up to access all valuation multiples
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
2005
8
Last FY Revenue n/a
Last FY EBITDA $2.9M
$8.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, ProMIS Neurosciences achieved revenue of n/a and an EBITDA of $2.9M.
ProMIS Neurosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ProMIS Neurosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $2.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$19.8M | XXX | -$16.8M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$8.3M | XXX | $2.8M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ProMIS Neurosciences's stock price is $1.
ProMIS Neurosciences has current market cap of $17.0M, and EV of $8.6M.
See ProMIS Neurosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.6M | $17.0M | XXX | XXX | XXX | XXX | $-0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ProMIS Neurosciences has market cap of $17.0M and EV of $8.6M.
ProMIS Neurosciences's trades at n/a EV/Revenue multiple, and 3.0x EV/EBITDA.
Equity research analysts estimate ProMIS Neurosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ProMIS Neurosciences has a P/E ratio of -2.1x.
See valuation multiples for ProMIS Neurosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17.0M | XXX | $17.0M | XXX | XXX | XXX |
| EV (current) | $8.6M | XXX | $8.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.1x | XXX | 6.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProMIS Neurosciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.1M for the same period.
ProMIS Neurosciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ProMIS Neurosciences's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ProMIS Neurosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ProMIS Neurosciences acquired XXX companies to date.
Last acquisition by ProMIS Neurosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . ProMIS Neurosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ProMIS Neurosciences founded? | ProMIS Neurosciences was founded in 2005. |
| Where is ProMIS Neurosciences headquartered? | ProMIS Neurosciences is headquartered in United States of America. |
| How many employees does ProMIS Neurosciences have? | As of today, ProMIS Neurosciences has 8 employees. |
| Who is the CEO of ProMIS Neurosciences? | ProMIS Neurosciences's CEO is Mr. Neil K. Warma. |
| Is ProMIS Neurosciences publicy listed? | Yes, ProMIS Neurosciences is a public company listed on NAS. |
| What is the stock symbol of ProMIS Neurosciences? | ProMIS Neurosciences trades under PMN ticker. |
| When did ProMIS Neurosciences go public? | ProMIS Neurosciences went public in 2005. |
| Who are competitors of ProMIS Neurosciences? | Similar companies to ProMIS Neurosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ProMIS Neurosciences? | ProMIS Neurosciences's current market cap is $17.0M |
| Is ProMIS Neurosciences profitable? | Yes, ProMIS Neurosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
